Glycosphingolipids are required for sorting melanosomal proteins in the Golgi complex.

Although glycosphingolipids are ubiquitously expressed and essential for multicellular organisms, surprisingly little is known about their intracellular functions. To explore the role of glycosphingolipids in membrane transport, we used the glycosphingolipid-deficient GM95 mouse melanoma cell line. We found that GM95 cells do not make melanin pigment because tyrosinase, the first and rate-limiting enzyme in melanin synthesis, was not targeted to melanosomes but accumulated in the Golgi complex. However, tyrosinase-related protein 1 still reached melanosomal structures via the plasma membrane instead of the direct pathway from the Golgi. Delivery of lysosomal enzymes from the Golgi complex to endosomes was normal, suggesting that this pathway is not affected by the absence of glycosphingolipids. Loss of pigmentation was due to tyrosinase mislocalization, since transfection of tyrosinase with an extended transmembrane domain, which bypassed the transport block, restored pigmentation. Transfection of ceramide glucosyltransferase or addition of glucosylsphingosine restored tyrosinase transport and pigmentation. We conclude that protein transport from Golgi to melanosomes via the direct pathway requires glycosphingolipids.

Monitoring extracellular glutamate in hippocampal slices with a microsensor.

The direct local assessment of glutamate in brain slices may improve our understanding of glutamatergic neurotransmission significantly. However, an analytical technique that monitors glutamate directly in brain slices is currently not available. Most recording techniques either monitor derivatives of glutamate or detect glutamate that diffuses out of the slice. Microsensors provide a promising solution to fulfill this analytical requirement. In the present study we have implanted a 10 microm diameter hydrogel-coated microsensor in the CA1 area of hippocampal slices to monitor extracellular glutamate levels. The influence of several pharmacological agents, which facilitate glutamate release from neurons or astrocytes, was investigated to explore the applicability of the microsensor. It was observed that KCl, veratradine, alpha-latrotoxine (LTX), DL-threo-beta-benzyloxyaspartate (dl-TBOA) and L-cystine rapidly increased the extracellular glutamate levels. As far as we know this is the first study in which a microsensor is applied to monitor dynamic changes of glutamate in brain slices and in our opinion this type of research may contribute greatly to improve our understanding of the physiology of glutamatergic neurotransmission.

A novel and simple method for endotracheal intubation of mice.

Endotracheal intubation in mice is necessary for experiments involving intratracheal instillation of various substances, repeated pulmonary function assessments and mechanical ventilation. Previously described methods for endotracheal intubation in mice require the use of injection anaesthesia to immobilize the animal during the intubation procedure or the use of a volatile anaesthetic prior to intubation for immobilization. With these methods, the control of anaesthetic depth during the intubation procedure is absent. We describe a method for simple and rapid intratracheal intubation in mice for mechanical ventilation, using a self-built plastic support to facilitate the intubation procedure. General anaesthesia is maintained by means of inhalation through a non-rebreathing circuit connected to the plastic support. This set-up gives the operator control of anaesthetic depth and sufficient time to perform the intubation procedure. A purpose-made laryngoscopic blade is used to facilitate the intubation tube entering the trachea. The blade of the purpose-made laryngoscope is constructed as a retraction guide and is curved for easy handling. Under direct vision, the epiglottis is gently lifted by the laryngoscopic blade while the intubation tube is pushed into the trachea. Following this novel intubation technique, we were able to mechanically ventilate mice for at least 2 h without severely disturbing blood gases. Histological evaluation of the lungs and microscopic evaluation of the trachea and larynx showed no signs of trauma related to the intubation technique or mechanical ventilation.

Changes in dopamine levels and locomotor activity in response to selection on virgin lifespan in Drosophila melanogaster.

Among various other mechanisms, genetic differences in the production of reactive oxygen species are thought to underlie genetic variation for longevity. Here we report on possible changes in ROS production related processes in response to selection for divergent virgin lifespan in Drosophila. The selection lines were observed to differ significantly in dopamine levels and melanin pigmentation, which is associated with dopamine levels at eclosion. These findings confirm that variation in dopamine levels is associated with genetic variation for longevity. Dopamine has previously been implied in ROS production and in the occurrence of age-related neurodegenerative diseases. In addition, we propose a possible proximate mechanism by which dopamine levels affect longevity in Drosophila: We tested if increased dopamine levels were associated with a "rate-of-living" syndrome of increased activity and respiration levels, thus aggravating the level of oxidative stress. Findings on locomotor activity and oxygen consumption of short-lived flies were in line with expectations. However, the relation is not straightforward, as flies of the long-lived lines did not show any consistent differences in pigmentation or dopamine levels with respect to the control lines. Moreover, long-lived flies also had increased locomotor activity, but showed no consistent differences in respiration rate. This strongly suggests that the response for increased and decreased lifespan may be obtained by different mechanisms.

In vivo monitoring of extracellular glutamate in the brain with a microsensor.

Recent discoveries have revealed that glutamatergic neurotransmission in the central nervous system is mediated by a dynamic interplay between neurons and astrocytes. To enhance our understanding of this process, the study of extracellular glutamate is crucial. At present, microdialysis is the most frequently used analytical technique to monitor extracellular glutamate levels directly in the brain. However, the neuronal and physiological origin of the detected glutamate levels is questioned as they do not fulfil the classical release criteria for exocytotic release, such as calcium dependency or response to the sodium channel blocker tetrodotoxine (TTX). It is hypothesized that an analytical technique with a higher spatial and temporal resolution is required. Glutamate microsensors provide a promising analytical solution to meet this requirement. In the present study, we applied a 10 micro m diameter hydrogel-coated glutamate microsensor to monitor extracellular glutamate levels in the striatum of anesthetized rats. To explore the potential of the microsensor, different pharmacological agents were injected in the vicinity of the sensor at an approximate distance of 100 micro m. It was observed that KCl, exogenous glutamate, kainate and the reuptake inhibitor DL-threo-beta-benzyloxyaspartate (DL-TBOA) increased the extracellular glutamate levels significantly. TTX decreased the basal extracellular glutamate levels approximately 90%, which indicates that the microsensor is capable of detecting neuronally derived glutamate. This is one of the first studies in which a microsensor is applied in vivo on a routine base, and it is concluded that microsensor research can contribute significantly to improve our understanding of the physiology of glutamatergic neurotransmission in the brain.

In vivo continuous and simultaneous monitoring of brain energy substrates with a multiplex amperometric enzyme-based biosensor device.

Enzyme-based amperometric biosensors are widely used for monitoring key biomarkers. In experimental neuroscience there is a growing interest in in vivo continuous and simultaneous monitoring of metabolism-related biomarkers, like glucose, lactate and pyruvate. The use of multiplex biosensors will provide better understanding of brain energy metabolism and its role in neuropathologies such as diabetes, ischemia, and epilepsy. We have developed and characterized an implantable multiplex microbiosensor device (MBD) for simultaneous and continuous in vivo monitoring of glucose, lactate, and pyruvate. First, we developed and characterized amperometric microbiosensors for monitoring lactate and pyruvate. In vitro evaluation allowed us to choose the most suitable biosensors for incorporation into the MBD, along with glucose and background biosensors. Fully assembled MBDs were characterized in vitro. The calculated performance parameters (LOD, LR, LRS, IMAX and appKM) showed that the multiplex MBD was highly selective and sensitive (LRS≥100 nA/mM) for each analyte and within an adequate range for in vivo application. Finally, MBDs were implanted in the mPFC of anesthetized adult male Wistar rats for in vivo evaluation. Following an equilibration period, baseline brain levels of glucose (1.3±0.2 mM), lactate (1.5±0.4 mM) and pyruvate (0.3±0.1 mM) were established. Subsequently, the MBDs recorded the responses of the animals when submitted to hyperglycemic (40% glucose i.v.) and hypoglycemic (5 U/kg insulin i.v.) challenges. Afterwards, MBDs were recalibrated to convert electrochemical readings into accurate substrate concentrations and to assess biofouling. The presented MBD can monitor simultaneously multiple biomarkers in vivo.

Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?

BACKGROUND: We investigated the combination of selective serotonin reuptake inhibitors (SSRIs) with the beta-adrenoceptor/serotonin 1A (5-HT(1A)) antagonist pindolol, based on the concept that 5-HT(1A) receptor blockade would eliminate the need for desensitization of presynaptic 5-HT(1A) receptors and therefore hasten the onset of action and improve the efficacy of SSRIs. However, since pindolol plasma levels after 2.5 mg three times a day are about 60 nmol/L, and the K(i) for the 5-HT(1A) receptor is 30 nmol/L, it is questionable whether pindolol levels in the brain would be sufficient to antagonize 5-HT(1A) receptors. Using microdialysis in the guinea pig, we correlated brain and plasma levels of pindolol with its capability of augmenting paroxetine-induced increases in brain 5-HT levels. In addition, central beta-receptor antagonism of pindolol was studied by investigating blockade of beta-agonist-induced increases in brain cyclic adenosine monophosphate (cAMP) formation. METHODS: Using microdialysis and jugular vein catheterization, we studied the ability of systemically administered pindolol to antagonize central 5-HT(1A) and beta-adrenoceptors, while simultaneously monitoring pindolol plasma and brain concentrations. RESULTS: Augmentation of paroxetine-induced increases in extracellular 5-HT levels in the ventral hippocampus was only observed at steady state plasma levels exceeding 7000 nmol/L (concurrent brain levels 600 nmol/L). In contrast, antagonism of beta-agonist-induced increases of brain cAMP levels was already observed at pindolol plasma levels of 70 nmol/L (concurrent brain levels < 3 nmol/L). CONCLUSIONS: At plasma levels that are observed in patients after 2.5 mg three times a day ( approximately 60 nmol/L), pindolol produces only a partial blockade of presynaptic 5-HT(1A) autoreceptors and does not augment the SSRI-induced 5-HT increase in the guinea pig brain. It is therefore very unlikely that the favorable effects of combining pindolol with SSRIs, as reported in a number of clinical studies, are due to 5-HT(1A) antagonism. Since pindolol completely blocks central beta-adrenoreceptors at clinically relevant plasma levels, it is possible that beta-adrenoceptor antagonism is involved in mediating pindolol's beneficial effects.

Circadian variation of catecholamine excretion in rats: correlation with locomotor activity and effects of drugs.

Rats housed in metabolic cages were used to study the circadian variation in the urinary excretion of free catecholamines. Small samples of urine (25-100 microliter) were analyzed for adrenaline, noradrenaline and dopamine by high pressure liquid chromatography (HPLC) and electrochemical detection. Various ways in which the values for excretion of catecholamines can be expressed (per min; per ml; per mmol creatinine; as ratio over dopamine) were calculated and discussed. Correction for excretion of creatinine resulted in the lowest variations coefficient among the experimental data. The correction for creatinine removed the circadian rhythm present in the output of noradrenaline (NA) and dopamine (DA). Adrenaline corrected for creatinine still displayed a pronounced circadian variation which was related to the overall locomotor activity of the animals (as recorded by photocells). Collection of 1 hr samples instead of 3 hr samples resulted in a worsening of the relationship between the excretion of adrenaline and locomotor activity. Finally, the possibility that the DA antagonist haloperidol, the DA agonist dipropyl-5,6-2-amino-6,7-dihydroxytetrahydronaphtalene (dipropyl-5,6 ADTN) and the alpha-antagonist phentolamine, could modify the excretion of free urinary catecholamines was investigated. Haloperidol and 5,6-dipropyl-ADTN did not change the output of the catecholamines, but phentolamine induced a strong increase in the excretion of NA. The latter observation suggest that at least part of the excretion of NA may originate from peripheral noradrenergic neurotransmission.

Synthesis of isomeric thienobenzothiazines and their effect on dopamine metabolism in rat brain.

The synthesis of the thieno[2,3-b]-, thieno[3,4-b]- and thieno[3,2-b]benzothiazines with a hydroxyethylpiperazinylpropyl side chain and various 2 substituents is described. The influence of these neuroleptic compounds on dopamine metabolism in vivo is quantitated by determining the rise in homovanillic acid concentrations in rat corpus striatum. Notable differences in activity were found among the isomers, which were useful for structure--activity correlations in the phenothiazine neuroleptics.

Synthesis and pharmacological evaluation of conformationally restricted phenothiazine analogues.

The synthesis of 3-(dimethylamino)-2,3-dihydro-4-chloro-1H-pyrido[3,2,1-kl]phenothiazine, its 10-chloro analogue, and two chloro isomers of 2[(dimethylamino)methyl]-2,3-dihydro-1H-pyrido[3,2,1-kl]phenothiazine is described. In these compounds the side chain of chlorpromazine is fixed into a certain position in order to study the dopamine-overlap theory and the role of the substituents in the phenothiazine neuroleptics. The compounds were tested for their influence on dopamine metabolism, while for the second set their ability to displace [3H]spiroperidol from dopamine receptors was assessed. No neuroleptic activity was found from the pharmacological data. The results are discussed on the basis of conformational requirements for dopamine antagonistic activity.

Effects of neostigmine and atropine on basal and handling-induced acetylcholine output from ventral hippocampus.

The involvement of muscarinic autoreceptors in the regulation of hippocampal acetylcholine levels during acetylcholinesterase inhibition was examined by perfusing the acetylcholinesterase inhibitor neostigmine bromide (10, 100 or 1000 nM) alone and in the presence of the muscarinic receptor antagonist atropine methylnitrate (10 microM), in resting and behaviourally-activated animals. In resting animals, local perfusion of neostigmine caused a dose-dependent increase in acetylcholine levels. Coadministration of atropine did not affect basal levels in the presence of 10 nM neostigmine, but increased acetylcholine levels approximately four and 11-fold in the presence of 100 nM and 1000 nM neostigmine, respectively. In animals which were behaviourally activated by handling, acetylcholine levels increased two- to three-fold in the presence of all neostigmine concentrations. However, the handling-induced increase in acetylcholine levels was somewhat smaller with 1000 nM neostigmine as compared to 10 nM neostigmine. Atropine had no effect on handling-induced acetylcholine output in the presence of 10 nM neostigmine, but caused greater and longer increases in the presence of 100 nM and 1000 nM neostigmine. These data indicate that acetylcholine levels are greatly reduced by autoinhibition at higher levels of acetylcholine esterase inhibition. The handling-evoked increase in acetylcholine levels is only moderately affected by the level of acetylcholinesterase inhibition, despite the participation of autoreceptors in the handling effect at higher levels of acetylcholinesterase inhibition.

A microdialysis study on pineal melatonin rhythms in rats after an 8-h phase advance: new characteristics of the underlying pacemaker.

This study describes the use of the microdialysis technique to elucidate specific properties of the circadian pacemaking system in the hypothalamus, by measurement of melatonin production in the pineal gland. Melatonin has appeared to be a reliable marker of the pacemaker activity, which is influenced by the light/dark cycle. A phase shift in the light/dark cycle was applied to perturb the rhythm generating system. An 8-h phase advance resulted in the disappearance of melatonin production over two days, with basal levels comparable to normal daytime levels. In the subsequent return of rhythmic melatonin production, new clock characteristics could be revealed, due to the high time-resolution measurements of microdialysis. While half of the animals still did not show any rhythmicity, the other half of the animals regained rhythmicity with entrained onset of melatonin production, while the offset was variable and not stably entrained to lights on. Ten days after the shift, the system had completely recovered and all animals regained normal rhythmicity, in phase with the new light/dark cycle. The results are interpreted in terms of the two-oscillator model, with one oscillator reacting with a phase advance and the other with a phase delay to adapt to the phase shift.

Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain.

RATIONALE: Previously, we have shown that the atypical antipsychotics clozapine and risperidone, unlike haloperidol, decreased the firing rate of substantia nigra reticulata (SNR) neurons. As the SNR receives substantial input from the striatum, an area where motoric side-effects of antipsychotics are thought to be mediated, the SNR might be an interesting brain structure with regard to motor side-effects. OBJECTIVE: The newly developed atypical antipsychotic olanzapine was studied for its effects on the firing rate of SNR cells. In addition, to gain insight in the implications of our experimental setup for clinical use, responses upon clozapine, olanzapine and haloperidol were studied after chronic treatment. METHODS: In chloralhydrate-anaesthetized male Wistar rats, extracellular recordings were made from SNR neurons upon intravenously (i.v.) administered cumulative doses of the antipsychotics. Naive rats and rats that were subcutaneously (SC) injected for 21 days with an antipsychotic were used. RESULTS: Olanzapine (50-1600 mg/kg; i.v.), significantly inhibited the firing rate of the SNR neurons. Upon 21 days of treatment with a daily SC injection of 20 mg/kg clozapine, the challenge on day 22 with cumulative injections of clozapine (200 6400 mg/kg; i.v.) significantly inhibited the firing rate of the SNR neurons. Olanzapine (50-1600 mg/kg; i.v.) also significantly inhibited the SNR activity when pretreated with olanzapine in an SC administered dose of 1 mg/kg, but not 5 mg/kg. Haloperidol (12.5-800 microg/kg; i.v.) did not significantly affect the SNR activity in rats pretreated with SC administered 0.5 mg/kg haloperidol. CONCLUSIONS: Upon acute and chronic administration of clozapine and olanzapine versus haloperidol, differential effects on SNR neuronal firing could be obtained. The experimental setup seem to be valid for further studies into the mechanism of action of typical versus (relatively low doses of) atypical antipsychotics. The implications of the inhibitory effect of atypical antipsychotics on the SNR firing rate are presently unknown, but could be associated with the lower propensity to induced motoric side-effects. On the other hand, the SNR activity might also reflect non-motoric activity possibly related to negative symptoms.

Sequence and significance of dopamine metabolism in the rat brain.

This commentary is a critical evaluation of research on the significance of dopamine (DA) metabolism in the striatum of the rat. The possible sequence of DA metabolism is discussed. Special reference was given to a possible differentiation between "intra-neuronal" and "extra-neuronal" formation of DA. In addition a possible relation between drug-induced changes in DA metabolite levels to processes as release and metabolism of the transmitters, was investigated. It is concluded that our understanding of DA metabolism is still far from clear. The only consistent finding at the present time is the fact that decreased DA release is reflected by decreased 3-MT levels. It is emphasized that one should investigate complete changes in the "fingerprint" of changes of DA metabolism rather than to rely on one or two metabolites, when the influence of a drug on dopaminergic transmission is to be established.

Simultaneous recording of the release of nigral and striatal dopamine in the awake rat.

The extracellular concentration of dopamine (DA) and 3,4-hydroxyphenylacetic acid (DOPAC) were estimated in the substantia nigra and striatum by microdialysis. The dialysate content of DA increased at least 10-fold when nomifensine (5 mumol/l) was infused into the nigra via the dialysis membrane. To improve the analytical chemical detection of DA, nomifensine was infused continually during all the dialysis experiments that were carried out in the substantia nigra. Dendritic as well as terminal release of DA were inhibited for several hours when the nerve impulse flow in dopaminergic neurons was blocked by systemic administration of gamma-butyrolacton (750 mg/kg, i.p.). Perfusion of tetrodotoxin through the nigra (1 mumol/l) produced a complete disappearance of nigral DA release and a somewhat variable decrease in the release of striatal dopamine. When tetrodotoxin was infused into the nigra, the DOPAC output from the nigra was unchanged, but striatal DOPAC increased to about 300% of controls. These results show that the dendritic release of DA fulfills classical release criteria: it possesses an effective uptake-mechanism, it is dependent on the opening of fast-sodium channels and it is related to drug-induced changes in impulse-flow activity.

In vivo evidence for the existence of autoreceptors on dopaminergic, serotonergic, and cholinergic neurons in the brain.

Intrastriatal infusions as well as systemic administration of the selective D-2 antagonist (-)-sulpiride caused similar increases in the dialysate levels of dopamine (DA) to about 180% of controls. A similar conclusion was drawn when the selective D-2 agonist (-)-N-0437 was infused intrastriatally or administered systemically: both routes of administration caused a decrease in the release of DA to about 40-50% of controls. In order to evaluate the properties of synthesis-modulating autoreceptors on dopaminergic and serotonergic neurons we have estimated the synthesis rate of serotonin (5-HT) or DA by monitoring the 5-HTP or DOPA formation in the dialysates during infusion of a decarboxylase inhibitor. Infusion of (-)-N-0437 decreased the DOPA formation, whereas infusion of (-)-sulpiride increased the dialysate levels of DOPA; these results indicate that the D-2 receptors controlling the synthesis of DA are localized on nerve terminals. Administration of the selective 5-HT-IA agonist 8-hydroxy-dipropyl-aminotetraline (8-OH-DPAT) resulted in a decrease in the synthesis rate of 5-HT. When 8-OH-DPAT was infused via the dialysis membrane, the agonist was unable to modify the release of 5-HT. The effects of infusion of the muscarinic agonist oxotremorine and the muscarinic antagonist atropine were dependent on the presence of the esterase inhibitor neostigmine in the perfusion fluid. In the absence of neostigmine, oxotremorine caused a pronounced decrease in the output of acetylcholine (ACh), whereas atropine was without effect. In the presence of neostigmine oxotremorine was without effect but infusion of atropine or other anticholinergics caused a pronounced increase in the dialysate levels of ACh. It is concluded that the autoreceptor controlling the release of ACh is of the M3-type and that the receptor is not fully occupied during normal conditions. In conclusion, microdialysis of neurotransmitters is a valuable tool for the study of autoreceptors in vivo. The presented studies provided evidence for the existence of autoreceptors controlling the synthesis and/or release of DA, 5-HT, as well as ACh in the striatum.

Effect of neostigmine on the hippocampal noradrenaline release: role of cholinergic receptors.

The effect of the cholinesterase inhibitor neostigmine on hippocampal noradrenaline (NA) release was studied using in vivo microdialysis. Local application of neostigmine significantly increased the release of NA. The effect was potentiated by coperfusion of the nicotinic antagonist mecamylamine but was completely blocked by the muscarinic antagonist atropine. The neostigmine-evoked NA release was not affected by the M2-selective muscarinic antagonist gallamine but was completely blocked by the M1-selective muscarinic antagonist pirenzepine. While muscarinic antagonists had no effect on the resting release of NA, mecamylamine increased it. Our data indicate that acetylcholine can stimulate the hippocampal NA release via M1 muscarinic receptors and that a population of nicotinic receptors mediate inhibitory tone on hippocampal NA release. The fact that neostigmine is able to enhance both cholinergic and noradrenergic neurotransmission may help to understand the beneficial effect of cholinesterase inhibitors in Alzheimer's disease.

Striatal dopamine-glutamate interactions reflected in substantia nigra reticulata firing.

To gain insight into the role of striatal dopamine in basal ganglia functioning, dopaminergic drugs alone and in combination with the glutamate receptor agonist kainic acid were infused in the lateral striatum via a microdialysis probe, while single-unit recordings of substantia nigra reticulata neurons were made in chloral hydrate-anaesthetized rats. Striatal infusion of dopaminergic drugs did not significantly affect the firing rate of substantia nigra reticulata neurons, which was related to the low activity of striatal cells under basal conditions, illustrated by the lack of effect of striatal infusion of TTX on substantia nigra reticulata activity. Under glutamate-stimulated conditions, striatal infusion of d-amphetamine potentiated the inhibition of substantia nigra reticulata neurons induced by striatal kainic acid. Thus, under stimulated but not basal conditions, the modulatory role of dopamine in the striatum could be demonstrated. Dopamine potentiated the inhibitory effect of striatal kainic acid on the firing rate of the basal ganglia output neurons.

A method to evaluate the diffusion rate of drugs from a microdialysis probe through brain tissue.

For interpretation of microdialysis experiments in which compounds are applied retrodialysis, it is important to have information about the migration rate of the infused compounds. Here we describe a dual-probe microdialysis method that can be used to evaluate the penetration rate of the infused drug. The basic idea is that not the drug itself is assayed, but that its pharmacological effect is recorded by a second probe positioned at a fixed distance (1 mm) of the infusion probe. Using this approach several compounds, each known to induce specific changes in the extracellular levels of dopamine, were infused into the striatum of the rat. The results indicate that the penetration rate of the pharmacological effect of infused compounds differed widely. No effects were seen at the second probe when high potassium chloride was infused. Apparently dopamine was not able to migrate into brain tissue over a distance of 1 mm. Low penetration rates were observed for the dopamine antagonist sulpiride, the dopamine agonist LY17155, and for amphetamine and nomifensine. A very high penetration rate was observed in case of tetrodotoxin. The fast effects of TTX could also be explained by remote inhibition of neurons passing along the infusion probe. The present study showed that most of the compounds have rather slow infusion rates, indicating that relatively high infusion concentrations are needed (1-10 mM) to reach substantial brain concentrations at a distance of 1 mm from the infusion probe.

Dopamine-acetylcholine interaction in the striatum studied by microdialysis in the awake rat: some methodological aspects.

In order to evaluate the dopamine/acetylcholine balance hypothesis, sulpiride, (-)-N-0437, oxotremorine or physostigmine were administered intraperitoneally to rats, whereas the extracellular levels of acetylcholine and dopamine in the striatum were recorded by microdialysis. The changes in dialysate concentration of the transmitters did not support the supposed interaction between dopaminergic and cholinergic neurons. Next, we infused direct and indirect dopamine agonists such as (-)-N-0437, amphetamine and nomifensine via the dialysis membrane. The dopamine agonists had no effect on the release of acetylcholine when the calcium concentration of the perfusion fluid was 3.4 mmol/l, but the agonists effectively inhibited the release of the transmitter when the calcium concentration was 1.2 mmol/l. The cholinergic drugs physostigmine, oxotremorine, atropine did not affect the release of dopamine.